EUCTR2020-002463-61-ES进行中（未招募）1 期
A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential Tremor
Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.0 个研究点目标入组 400 人开始时间: 2021年12月20日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent.
- •2. Participants who are diagnosed with ET (including ET plus) according to the MDS Consensus Statement on the Classification of Tremors from the Task Force on Tremor of the International Parkinson's and Movement Disorder Society.
- •3. Participants have moderate to severe disability associated with tremor as determined by a score of = 22 on the TETRAS-ADL subscale; and a score of > 5 on the sum of items 6 and 7 of the TETRAS-PS; and a CGI-S rating of at least moderate for participants' ability to function.
- •4. Sex and Contraceptive/Barrier Requirements
- •During the study intervention and for at least 30 days after the last dose of study intervention male participants must refrain from donating sperm. Non-abstinent males must agree to use a male condom in combination with female partner use of a highly effective contraceptive method with a failure rate of < 1% per year. All male participants must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.
- •Female participants must not be pregnant or breastfeeding, are either women of non-childbearing potential (WONCBP), or are women of childbearing potential (WOCBP) using a highly effective contraceptive method with a failure rate of < 1% during the study intervention period and for at least 30 days after the last dose of study intervention. Male partners of WOCBP are required to use barrier protection, eg, condoms, over the same 30 day period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 297
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 103
排除标准
- •1. Known history or current evidence of other medical or neurological conditions that may cause or explain the participant's tremor.
- •2. Severe cognitive impairment as defined by a Montreal Cognitive Assessment (MoCA; score <23), or has cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent.
- •3. Current suicidal risk as determined from history, by presence of active suicidal ideation as indicated by positive response to item 4 or 5 on the C-SSRS (within the past 24 months), or any history of suicide attempt; current or past (within 1 year) major depressive episode according to DSM-5 criteria.
- •4. History (within past 2 years at screening) or presence of substance use disorder (including alcohol) according to DSM-5 criteria, known drug dependence, or seeking treatment for alcohol or substance abuse related disorder. Nicotine use disorder is excluded if it impacts tremor.
- •5. Prior magnetic resonance (MR)-guided focused ultrasound, surgical intervention (eg, deep brain stimulation, ablative thalamotomy, gamma knife thalamotomy), or inability to refrain from using a device for treatment of tremor for the duration of the treatment period.
- •6. Botulinum toxin injection in the 6 months before screening or planned use at any time during the study.
- •7. Treatment with any medication that could affect the evaluation of tremor within 2 weeks or 5 half-lives (whichever is longer) before screening or planned use at any time during the study.
- •8. Use of prescription or nonprescription drugs or other products known to be inducers of CYP3A4 that are known to decrease AUC by > 30%,, which cannot be discontinued at least 4 weeks before Baseline, or planned use at any time during the study.
- •9. Use of prescription or nonprescription drugs, or other products (eg, grapefruit, grapefruit juice, or Seville oranges) known to be strong or moderate inhibitors of CYP3A4 , that cannot be discontinued 2 weeks or 5 half-lives, whichever is longer, before Baseline or planned use at any time during the study.
- •10. Use of proton pump inhibitors and histamine-2 receptor antagonists, which cannot be discontinued at least 2 weeks before Baseline, or planned use at any time during the study (occasional use of antacids will be permitted, but antacids should be taken at least 4 hours apart from study intervention).
- •11. Inability to refrain from use of medication/substance(s) that might produce tremor or interfere with the evaluation of tremor on study visit days, such as, but not limited to, stimulant decongestants, beta-agonist bronchodilators, and alcohol.
- •12. Regular use of more than 3 units of alcohol per day.
- •13. Regular consumption of caffeine > 400 mg/day or > 4 cups of coffee per day.
研究者
相似试验
进行中（未招募）
1 期
A Study of JZP385 in Adults with Moderate to Severe Essential Tremor (ET)Essential Tremor (ET)MedDRA version: 21.1Level: PTClassification code 10015496Term: Essential tremorSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-002463-61-DECavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.400
进行中（未招募）
1 期
A Study of JZP385 in Adults with Moderate to Severe Essential Tremor (ET)EUCTR2020-002463-61-PLCavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.400
进行中（未招募）
1 期
A 12-week study to investigate the effect and safety of AZD7624 treatment compared to placebo (inactive substance) in COPD Patients when administered together with the patients' regular COPD TherapyChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-001053-16-NLAstraZeneca AB212
已完成
2 期
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients with a History of Frequent Acute Exacerbations while on Maintenance TherapyCOPD10006436obstructive lung diseaseNL-OMON41136Astra Zeneca18
进行中（未招募）
不适用
A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised,Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668Administered Orally Twice Daily on Structural Changes in the Airwaysby Multi-Slice Computed Tomography (MSCT) in Patients with ChronicObstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10010952Term: COPDEUCTR2009-014594-40-NLAstraZeneca AB50